Press Releases

Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023 AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023 Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors NEW YORK , March 15, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and

NEW YORK , March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other

NEW YORK , Feb. 16, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

NEW YORK , Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

NEW YORK , Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. ,  a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilization First immune cell therapy

-  Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting -  R&D Day on November 10, 2022 , from 4:00-6:00pm ET in Boston and via webcast NEW YORK , Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc ., a clinical-stage

Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ET NEW YORK , Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T

Experts in disease pathways discuss clinical data of allo-iNKTs R&D strategy driving pipeline momentum, productivity, and innovation Internal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 doses R&D event: November 10 th from 4:00-6:00 pm ET , Boston, MA , and

Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumors Clinical data of AgenT-797 in viral ARDS and refractory multiple myeloma New therapeutic candidates: 1) MiNK-215, an allo-FAP-CAR-iNKT; 2) MiNK-413, allo- armored -BCMA-CAR-iNKT NEW YORK , Oct.

NEW YORK , Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023 Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022 Under the leadership team of Dr. Joy Zhou , completed internal cGMP production of AgenT-797 with expansion capacity to treat >700,000

NEW YORK , Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Conference Call on Tuesday, August 9th 2022, at 11:00 a.m. ET NEW YORK , July 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T

NEW YORK , May 25, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Clinical updates from solid tumor cancers and ARDS with allo-agenT-797 are on track for 2H 2022 GMP manufacturing launch in 1H 2022 with target 10,000 doses/yr BCMA-CAR-iNKT and stromal-CAR-iNKT preclinical results 2H 2022 Ended First Quarter with $34.7M in cash with a projected 2022 cash burn of

NEW YORK , April 27, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

AgenT-797 (Allo-iNKTs) +/- anti-PD-1 clinical trial underway in solid tumor cancers Benefit in severe COVID-19 ARDS shows 75% survival rate in patients treated with Allo-iNKTs AgenT-797 treatment with no lymphodepletion shows no cytokine release syndrome or neurotoxicity 2021 annualized cash burn

NEW YORK , March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated

Clinical data show AgenT-797 can be dosed to 1 billion cells without lymphodepletion, with no evidence of cytokine release syndrome or neurotoxicity Clinical trials underway in solid tumor cancers, multiple myeloma, and viral ARDS NEW YORK , March 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , a

NEW YORK , Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,

NEW YORK , Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases

No evidence of neurotoxicity or cytokine release syndrome Early signals of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma iNKTs demonstrated potent tumor killing in solid tumor models NEW YORK , Nov.

NEW YORK , Nov. 09, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases,